Protalex, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.protalex.com
Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02566603
- Locations
- 🇫🇷
Haut-Levêque Hospital, Pessac, Bordeaux, France
🇫🇷CH Lyon Sud, Pierre-Bénite, Lyon, France
🇫🇷Côte de Nacre Hospital, Caen, France
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02401061
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Michigan Center of Medical Research, Farmington Hills, Michigan, United States
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02330445
- Locations
- 🇺🇸
Protalex Investigational Site, Coeur d'Alene, Idaho, United States
Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01749787
- Locations
- 🇺🇸
Protalex Investigative Site, Los Angeles, California, United States
🇺🇸Protalex Investigational Site, Allen, Texas, United States
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
- Conditions
- Idiopathic Thrombocytopenic Purpura (ITP)
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00571467
- Locations
- 🇦🇺
Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺St. George Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane, Brisbane, Queensland, Australia
- Prev
- 1
- 2
- Next